Vetanco at the Global Conference on Vaccines Research and Development

The laboratory was part of the “Global Conference on Vaccines Research and Development”, which was held in Spain this past 5^th and 6^th of December.

As part of their international stance as a scientific innovation leader, Vetanco, the international veterinary laboratory developing, manufacturing and marketing innovative products for animal health and production for over 35 years now, was part of the “Global Conference on Vaccines Research and Development” (Conferencia mundial sobre investigación y desarrollo de vacunas), which was held at the AC Hotel by Marriott Sevilla, Forum Sevilla, Spain, this past 5^th and 6^th of December.

There, Dr. Sherry Layton, Biological Scientific Director at Vetanco and BV Science, was the main presenter and moderator on the first day of the Conference. The event gathered the international vaccine research and development leaders, both in human and veterinary medicine.

During her presentation, Dr. Layton spoke about the future of world vaccinology and how the Biotech Vac platform fulfills all the premises of the “One Health” concept, through animal, people and environmental protection.

On his part, Dr. Emanuel Gumina, leader of the Vetanco Biotechnological Laboratory, presented the latest results of the Biotech Vac Salmonella vaccine to the world vaccine researchers and developers. During his presentation, he illustrated how the vaccine has succeeded in protecting poultry even highly challenging field conditions. In turn, he presented the long-life trials results, which showed the duration of protection — 110 weeks of life.

During the event and together with a large number of vaccine researchers and developers, Dr. Jeff Hall, Biological Research and Development Director at Vetanco USA, shared the efficiency results obtained during the first development stages of a vaccine for E. coli control in the Biotech Vac platform. This new vaccination candidate succeeded in avoiding the appearance of signs associated with colibacillosis in challenged poultry, proving there’s a promising future for its development ahead.

Lastly, Dr. Bruno Vecchi, Poultry Technical Manager for the laboratory, presented the results of an entire year using Biotech Vac COX vaccine in Latin America. After having vaccinated more than a million birds, during 3 consecutive cycles, the vaccine proved to be successful in reducing intestinal injuries caused by different species of Eimeria, as well as improving production parameters in comparison with the other control tools available in the market.

The aim of the event was to bring academic scientist, researchers and leading research scholars together to exchange and share their experiences and research results in every respect of vaccine research and development.